MEMSCAP And AXLR SATT Launch Technological Maturation Project for Medical Dialysis and Blood Filtration Applications
June 20 2017 - 1:30AM
Business Wire
After the EUROSTARS project for avionics
applications launched in Q4 2016 and financed by the French and
Norwegian authorities, this new project seals the partnership with
the LIRMM in the medical field
Regulatory News:
MEMSCAP (Paris:MEMS) (NYSE Euronext: MEMS), the leading provider
of innovative solutions based on MEMS (micro-electro-mechanical
systems) technology announces today the launch of a program of
co-design for integrated circuits (ASIC) with the AXLR
Technological Transfer Acceleration Company (SATT) and the
Montpellier Laboratory of Computer Science, Robotics and
Microelectronics (LIRMM) for piezoresistive pressure transducers
mainly targeting the medical applications of dialysis and blood
filtration.
The collaboration between MEMSCAP, the SATT AXLR and the LIRMM
aims at the implementation of research work carried out at LIRMM on
intelligent signal conditioning of resistive sensors. Patents
protecting this innovation filed by the CNRS and the University of
Montpellier have been granted and have been licensed by MEMSCAP as
part of this project. The total expected duration of the project is
18 months and includes the design, prototyping and validation of an
integrated circuit specific to the needs of MEMSCAP's medical
products and its integration into MEMSCAP products.
The promising innovation of the LIRMM directly addresses the
core technology of MEMSCAP aerospace and medical sensors which are
based on piezoresistive effect.
One of the functions of a hemodialysis machine is to measure and
display arterial and venous pressures as well as to notify the
operator when these pressures fluctuate outside of an established
alarm limit. Arterial and venous pressure monitoring provides
information regarding vascular access and the extracorporeal
circuit in which a patient's blood is circulating. Correct
interpretation of these pressures can:
- prevent hemolysis and microbubbles in
the blood tubing set from excessive negative pressure;
- assess vascular access for adequate
blood flow or problems such as venous stenosis; and,
- ensure accurate blood flow through the
dialyzer for optimal dialysis therapy.
MEMSCAP transducers are currently designed in multiple
hemodialysis equipments. Our transducers combine the required
accuracy, long-term stability, and sustain most of the aggressive
sterilization processes performed in these equipments and medical
procedures. Implementation of the LIRMM technology would help
provide sensors that significantly reduce the operational and
recurring maintenance and calibration costs of dialysis and
filtration machines.
This project extends the partnership between LIRMM and MEMSCAP
which, was initiated during the fourth quarter of 2016, within a
36-months EUROSTARS project funded by the French and Norwegian
authorities to adapt this signal conditioning technology to the
aerospace applications of Full Authority Digital Engine Control
(FADEC) and Air Data, Attitude and Heading Reference Systems
(ADHARS).
Specifications and details for MEMSCAP avionics products can be
obtained by contacting MEMSCAP at info@memscap.com or by contacting
our office in Skoppum, Norway.
About AXLRAxLR is a technology transfer acceleration
company. Our specialty is helping innovative projects derived from
academic research reach maturity and commercialization. We work
with the main public-sector research laboratories in France's
Mediterranean area in Occitanie, one of the most dynamic locations
in Europe, with over 200 laboratories and some 12,000 researchers.
For more information, please visit our web site www.axlr.com.
About MEMSCAPMEMSCAP is the leading provider of
innovative micro-electro-mechanical systems (MEMS)-based solutions.
MEMSCAP standard and custom products and solutions include
components, component designs (IP), manufacturing and related
services. MEMSCAP customers include Fortune 500 businesses, major
research institutes and universities. The company's shares are
traded on the Eurolist of NYSE Euronext Paris S.A (ISIN:
FR0010298620-MEMS). More information on the company's products and
services can be obtained at www.memscap.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005526/en/
MEMSCAPNicolas Bertsch, Ph: +33 4 76 92 85 00Chief
Operating Officernicolas.bertsch@memscap.comorMEMSCAPRoy
Grelland, Ph: 47 3308 4000General Manager, Standard Products
Business Unitroy.grelland@memscap.com
Matthews Emerging Market... (NASDAQ:MEMS)
Historical Stock Chart
From Jan 2025 to Feb 2025
Matthews Emerging Market... (NASDAQ:MEMS)
Historical Stock Chart
From Feb 2024 to Feb 2025